Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus VESICARE LS.
LUSEDRA vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
5 mg orally once daily.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category C
Category C
Anticholinergic
Anticholinergic